Comparison
Piracetam vs Alpha-GPC
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Alpha-GPC
The most bioavailable common choline source. About 40% of an oral dose reaches the brain within an hour, where it serves as substrate for acetylcholine synthesis and as a phospholipid membrane component. The de facto pairing for every racetam stack.
| Field | Piracetam | Alpha-GPC |
|---|---|---|
| Category | racetam | cholinergic |
| Dose range | 1200–4800mg | 300–600mg |
| Half-life | 5h | 6h |
| Onset | 45min | 30min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USUnscheduled | USOTC |
| PubMed refs | 1200 | 320 |
The comparison in plain English
Auto-generated from dataPiracetam and Alpha-GPC are both in the racetam (racetam) and cholinergic respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. Alpha-GPC The most bioavailable common choline source.
Bottom line
Piracetam (evidence A, safety 5/5) matches the evidence base of Alpha-GPC (evidence A, safety 5/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose Alpha-GPC if
Alpha-GPC is the better fit when your goal aligns with its mechanism (Rapidly absorbed and cleaved into choline and glycerophosphate) and the dose range (300–600mg) suits your protocol. Half-life is 6h.